TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Merck Life Science AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
1,230,130
|
1,305,238
|
1,251,207 |
| Financial expenses |
193
|
0
|
1,159 |
| Earnings before taxes |
655,620
|
710,028
|
672,573 |
| EBITDA |
624,968
|
670,825
|
669,081 |
| Total assets |
816,181
|
1,454,869
|
867,981 |
| Current assets |
801,975
|
1,440,851
|
853,998 |
| Current liabilities |
47,925
|
97,138
|
125,924 |
| Equity capital |
756,971
|
1,346,799
|
731,833 |
| - share capital |
10,622
|
10,434
|
9,743 |
| Employees (average) |
40
|
48
|
46 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
92.7%
|
92.6%
|
84.3% |
| Turnover per employee |
30,753
|
27,192
|
27,200 |
| Profit as a percentage of turnover |
53.3%
|
54.4%
|
53.8% |
| Return on assets (ROA) |
80.4%
|
48.8%
|
77.6% |
| Current ratio |
1673.4%
|
1483.3%
|
678.2% |
| Return on equity (ROE) |
86.6%
|
52.7%
|
91.9% |
| Change turnover |
-98,643
|
-34,751
|
372,232 |
| Change turnover % |
-7%
|
-3%
|
42% |
| Chg. No. of employees |
-8
|
2
|
17 |
| Chg. No. of employees % |
-17%
|
4%
|
59% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.